6533b82efe1ef96bd1293e4d
RESEARCH PRODUCT
Homocysteine Levels in Autism Spectrum Disorder: A Clinical Update
Milagros Fuentes-alberoOmar Caulisubject
Male0301 basic medicineHyperhomocysteinemiaAdolescentHomocysteineAutism Spectrum DisorderEndocrinology Diabetes and MetabolismCentral nervous systemHyperhomocysteinemiaChild BehaviorHomocysteine levelsBioinformaticsSeverity of Illness Index03 medical and health scienceschemistry.chemical_compoundChild Development0302 clinical medicinemental disordersSeverity of illnessHumansImmunology and AllergyMedicineChildHomocysteinebusiness.industryAge FactorsAdolescent DevelopmentPrognosismedicine.diseasePathophysiologyUp-Regulation030104 developmental biologymedicine.anatomical_structurechemistryAdolescent BehaviorAutism spectrum disorderChild PreschoolBiomarker (medicine)FemalebusinessBiomarkers030217 neurology & neurosurgerydescription
Background and objective Homocysteine (Hcy) is a non-protein α-amino acid, which plays several important roles in human physiology and in the central nervous system. Although Hcy has several known biological properties in one-carbon metabolism, its overproduction might be harmful, and could add to the pathophysiology associated with ASD. We reviewed the current evidence about changes in Hcy concentration in ASD and tried to correlate its changes with the clinical profile Discussion: The concentration of the amino acid in biological fluids (blood and urine) in children/ youngs with ASD is increased in the majority of studies when comparing to typically developing control subjects. Some report demonstrated a significant association between the severity of the disorder and the abnormalities in Hcy levels. Conclusion Further research is needed to correlate the increase in Hcy with specific symptoms/ deficits in ASD and to evaluate the clinical impact of strategies that can reduce Hcy concentration in ASD.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-11-01 | Endocrine, Metabolic & Immune Disorders - Drug Targets |